Brief: Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor

Ipsen SA

25/07/2024 06:08

July 25 (Reuters) - Ipsen SA  IPN.PA :
    * IPSEN AND DAY ONE ENTER INTO EXCLUSIVE EX-U.S. LICENSING
AGREEMENT TO COMMERCIALIZE TOVORAFENIB FOR THE MOST COMMON
CHILDHOOD BRAIN TUMOR
    * IPSEN SA - DAY ONE RECEIVES APPROXIMATELY $111 MILLION
UPFRONT
IN CASH AND EQUITY INVESTMENT
    * IPSEN SA - UP TO APPROXIMATELY $350 MILLION IN ADDITIONAL
LAUNCH
AND SALES MILESTONE PAYMENTS

Source text for Eikon:  ID:nGNE5WWWpD 
Further company coverage:  IPN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))